RE:RE:RE:Deal with.....pharmaAgreed, Nathan - but I do think - if the next 2 earnings reports show continued growth of med sales coupled with more positive test results related to cannabis med use, big pharma companies will move earlier than the norm - they will not want to be last to the dance. Medical is growing in small market Canada, but also Europe, and if it continues to look like the US will follow, a big first investment would make sense then I think. ACB has set itself up very well medically now, and I think the next couple of earnings will show that. Money will be helpful to market rec, but I think our strengths will start to shine in the next 12 months. It'll be nice if a big deal comes soon, but I think one will come, now or later, provided things continue on the current path. In a substantial way, the purchases of Cannimed and MedReleaf - which cost us in terms of short term share price - should help twofold: creating a big medical presence, and marketing ACB for the coming rec market. When people are prescribed med cannabis by doctors now, more often than not they go with what they believe are the oldest, most reliable names: those are Cannimed and MedReleaf, both prescriptions soon to be Aurora. THe more the name is out there, the more prevalent it will be for new clientele in the rec market. Exciting times.